Libtayo (cemiplimab)

pCPA File Number: 21898
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Sponsor/Manufacturer:
sanofi-aventis Canada Inc.
CADTH Project Number:
PC0262
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable